Email Medtest DX Medtest Headquarters Medtest Facebook Medtest Linkedin

Cocaine Metabolite


(Assays)

METHOD

DRI Urine Drug Screening

TECHNICAL INFORMATION

Format: Liquid
Wavelength: 340 nm
Linearity: 1000 ng/mL
Storage Temperature: 2 - 8° C
  • Description
  • Ordering Information
  • Related Products
  • Documentation

Intended Use

The DRI Cocaine Metabolite Enzyme Immunoassay is a homogeneous enzyme immunoassay intended for the qualitative and semi-quantitative determination of benzoylecgonine (Cocaine Metabolite) in human urine with either 300 ng/mL or 150 ng/mL as a cutoff calibrator.

Principle

The DRI® Cocaine Metabolite Assay is a homogeneous enzyme immunoassay using ready-to –use liquid reagents. The assay uses a specific antibody, which can detect benzoylecgonine in urine. The assay is based on the competition of an enzyme glucose-6-phosphate dehydrogenase (G6PDH) labeled drug and the drug from the urine sample for a fixed amount of specific antibody binding sites. In the presence of free drug from the sample, the free drug occupies the antibody binding sites, allowing the drug-labeled G6PDH to interact with the substrate, resulting in enzyme activity. In the absence of drug from the sample, the specific antibody binds to the drug labeled with G6PDH and the enzyme activity is inhibited. This phenomenon creates a direct relationship between the drug concentration in the urine and the enzyme activity. The enzyme G6PDH activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.